Efficacy and safety of anlotinib as a third‑line treatment of advanced non‑small cell lung cancer: A meta‑analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of anlotinib as a third‑line treatment of advanced non‑small cell lung cancer: A meta‑analysis of randomized controlled trials

Published:2022-05-27 Issue:1 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Zha Bowen¹,Zhang Yuxin²,Yang Runzi³,Kamili Muladili¹

Affiliation:

1. Department of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China

2. Department of Evidence‑Based Medicine, School of Public Health, Capital Medical University, Beijing 100069, P.R. China

3. Department of Education, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference43 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. The biology and management of nonsmall cell lung cancer;Herbst;Nature,2018

3. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin Proc,2008

4. Limited resection for early-stage non-small cell lung cancer as function-preserving radical surgery: A review;Aokage;Jpn J Clin Oncol,2017

5. Non-small cell lung cancer: Epidemiology, Screening, diagnosis, and treatment;Duma;Mayo Clin Proc,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study;Frontiers in Oncology;2023-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3